Know Where Topical Ruxolitinib Fits for Vitiligo and Eczema

Ruxolitinib (Opzelura) 1.5% cream will be the first topical JAK inhibitor for vitiligo and mild to moderate eczema in ages 12 and up.

Vitiligo is an autoimmune condition where the immune system attacks melanin cells leading to patchy loss of skin pigment.

Ruxolitinib improves skin pigmentation in vitiligo by preventing the attack on melanin cells...and improves eczema by reducing inflammation.